Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Observational Study of the LambdaGuide System for Measurement of Observable Genitourinary Anatomy During Cystoscopic Procedures in Men

27 octobre 2026 mis à jour par: Lambda Surgical, Inc

This prospective clinical study will evaluate the feasibility, performance, and safety of the LambdaGuide System for obtaining point-to-point measurements of observable genitourinary anatomy during cystoscopic procedures in adult men. The system is intended to provide measurements of anatomical structures visible during cystoscopy without influencing clinical diagnosis or treatment decisions.

The study will assess successful calibration, spatial capture, measurement point selection, and completion of point-to-point measurements. Device usability, procedural workflow effects, and adverse events will also be evaluated. Optional comparisons with known-dimension references may be performed for descriptive purposes.

LambdaGuide measurements will not be used to guide or modify clinical care.

Aperçu de l'étude

Statut

Recrutement

Les conditions

Description détaillée

This is a prospective, observational clinical study designed to evaluate the feasibility, functional performance, usability, and safety of the LambdaGuide System during cystoscopic procedures in adult male participants aged 22 years and older.

The LambdaGuide System is an investigational optical measurement system that integrates with a compatible cystoscope. It uses an optical camera module, calibration process, spatial capture, and software-based point selection to obtain point-to-point measurements of anatomical structures visible within the urinary tract.

Participants may include men undergoing non-emergency cystoscopic procedures and, where specifically authorized under the approved research protocol, healthy adult male volunteers. Study participation involves use of the LambdaGuide System during cystoscopic visualization. For patients undergoing clinically indicated cystoscopy, the investigational measurements are performed alongside standard clinical care. LambdaGuide measurements will not be used to make diagnostic or therapeutic decisions, select treatment, or modify standard clinical care.

During the procedure, qualified clinicians will set up the LambdaGuide System, perform calibration using an approved calibration target, and attempt measurements of observable urinary anatomy. Potential measurement targets include anatomical openings or narrowing, urethral strictures, distances between anatomical landmarks, urinary tract lesions, stones, foreign bodies, and implant-related structures.

For each measurement attempt, the study will document the ability to obtain spatial information, select two valid measurement points, and display a point-to-point measurement. The primary performance endpoint is procedure-level clinical measurement feasibility, defined as obtaining at least one successful point-to-point measurement during an evaluable procedure.

Additional assessments include calibration success, camera deployment and image display, spatial capture success, measurement completion, calibration and measurement time, procedural interference, and clinician-reported usability. Optional observational comparisons with known-dimension references may be performed. These comparisons are descriptive and are not intended to establish measurement accuracy.

Safety will be evaluated through documentation of adverse events, including their severity, seriousness, and relationship to the investigational device or study procedures. Device deficiencies and malfunctions will also be recorded. Participants will undergo post-procedure safety assessment and follow-up approximately 30 days after the procedure, within a permitted window of ±5 days.

The study is intended to characterize the LambdaGuide System's ability to obtain measurements of visible genitourinary anatomy in a clinical environment and to collect performance, usability, and safety data to support further device evaluation.

Type d'étude

Observationnel

Inscription (Estimé)

10

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

    • Massachusetts
      • Boston, Massachusetts, États-Unis, 02111
        • Recrutement
        • PINE (Prostate Institution of New England)
        • Contact:
        • Chercheur principal:
          • Louis Liou, MD, PhD

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

22 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Homme

Méthode d'échantillonnage

Échantillon non probabiliste

Population étudiée

No additional description beyond Eligibility Criteria. Subjects should be able to travel to a study site.

La description

Inclusion Criteria:

  1. Adult male subject (22 years of age or older).
  2. Subject who undergoes a non-emergency cystoscopic procedure, or a healthy volunteer.
  3. Able and willing to provide informed consent before study participation.
  4. Procedure is expected to provide visualization of observable urinary anatomy suitable for an attempted measurement.
  5. Investigator determines that study participation is appropriate and will not interfere with standard clinical care.
  6. Investigator determines, based on medical history and physical examination, that the subject is medically appropriate to undergo the study procedures.

Exclusion Criteria:

  1. Participation is expected to interfere with or materially delay standard clinical care.
  2. Known clinical condition or procedural circumstance that, in the investigator's judgment, makes study participation inappropriate.
  3. Inability to provide informed consent.
  4. Inability to use the required compatible cystoscope or approved study configuration.
  5. Known allergy or contraindication to the local anesthetic planned for the cystoscopic procedure.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Modèles d'observation: CASE_ONLY
  • Perspectives temporelles: PROSPECTIVE

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Clinical measurement feasibility
Délai: Procedure duration

Clinical measurement feasibility, assessed as a procedure-level pass/fail outcome. An evaluable procedure passes if at least one successful point-to-point measurement is obtained.

Procedure duration
Primary safety endpoint
Délai: From procedure date to 30 days after (+/-5 days)

Incidence, severity, seriousness, and relatedness of device-related, procedure-related, and other adverse events.

From procedure date to 30 days after (+/-5 days)

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Calibration success
Délai: During Procedure

Calibration success

During Procedure
Camera deployment and expected image display
Délai: During Procedure

Camera deployment and expected image display

During Procedure
Spatial capture success
Délai: During Procedure

Spatial capture success

During Procedure
Valid point-selection success
Délai: During Procedure

Valid point-selection success

During Procedure
Successful measurement completion
Délai: During Procedure

Successful measurement completion

During Procedure
Calibration and measurement time
Délai: During Procedure

Calibration and measurement time (descriptive only)

During Procedure
Procedure interference
Délai: During Procedure

Procedure interference

During Procedure
User acceptance
Délai: During Procedure

User acceptance - based on Investigator Questionnaire

During Procedure
Observational comparative measurements (
Délai: During Procedure

Observational comparative measurements (descriptive only)

During Procedure

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Louis Liou, MD, PhD, PINE - Prostate Institution of New England

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 novembre 2026

Achèvement primaire (Estimé)

1 octobre 2027

Achèvement de l'étude (Estimé)

1 octobre 2027

Dates d'inscription aux études

Première soumission

27 octobre 2026

Première soumission répondant aux critères de contrôle qualité

27 octobre 2026

Première publication (Réel)

3 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

3 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

27 octobre 2026

Dernière vérification

1 octobre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

INDÉCIS

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner